Camp4 Therapeutics CFO buys 6,551 shares

Camp4 Therapeutics Corp disclosed that its Chief Financial Officer, Kelly Gold, purchased 6,551 shares of common stock on August 3, 2026 at $1.65 per share.

Rhea-AI Filing Summary

Camp4 Therapeutics Corp disclosed that its Chief Financial Officer, Kelly Gold, purchased 6,551 shares of common stock on August 3, 2026 at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement with the issuer and various investors. Following this transaction, Gold directly owns 74,428 shares of Camp4 Therapeutics common stock. The Rule 10b5-1 checkbox was not marked for this transaction.

Insider Trade Summary

Net Buyer: 6,551 shares

Net Buy 1 txn

Insider Gold Kelly

Role Chief Financial Officer

Bought 6,551 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	6,551	$1.65	$11K

Holdings After Transaction: Common Stock — 74,428 shares (Direct)

Footnotes (1)

1. F1. On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Key Figures

Shares purchased: 6,551 shares Purchase price: $1.65 per share Post-transaction holdings: 74,428 shares +2 more

5 metrics

Shares purchased 6,551 shares Common stock bought on August 3, 2026

Purchase price $1.65 per share Price in second closing of private placement

Post-transaction holdings 74,428 shares Direct common stock owned by CFO Kelly Gold after purchase

Number of buy transactions 1 Count of purchase transactions reported in this Form 4

Net shares acquired 6,551 shares Net buy shares reported in transaction summary

Key Terms

private placement, Securities Purchase Agreement, institutional investors

3 terms

private placement financial

"acquired shares in the second closing of a private placement by the Issuer"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Securities Purchase Agreement financial

"pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

institutional investors financial

"by and among the Issuer and certain institutional investors and certain directors"

Institutional investors are large organizations, like pension funds, insurance companies, and mutual funds, that invest huge amounts of money on behalf of many people. Their decisions can influence the economy because they buy and sell big chunks of stocks, bonds, or other assets. They matter because their actions can affect market prices and trends.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Camp4 Therapeutics (CAMP) report for its CFO?

Camp4 Therapeutics reported that CFO Kelly Gold purchased 6,551 shares of common stock on August 3, 2026 at $1.65 per share. The buy occurred in the second closing of a private placement under a Securities Purchase Agreement.

How many Camp4 Therapeutics (CAMP) shares does the CFO own after this Form 4 transaction?

After the reported transaction, CFO Kelly Gold directly owns 74,428 shares of Camp4 Therapeutics common stock. This reflects the addition of 6,551 shares acquired in the August 3, 2026 private placement closing.

At what price did the Camp4 Therapeutics (CAMP) CFO buy shares in the private placement?

CFO Kelly Gold purchased the Camp4 Therapeutics shares at a price of $1.65 per share. The footnote states this price applied in the second closing of a private placement conducted under a Securities Purchase Agreement with various investors.

Was the Camp4 Therapeutics (CAMP) CFO’s share purchase made under a Rule 10b5-1 plan?

The filing indicates that the Rule 10b5-1 checkbox was not marked for this transaction. That means the reported August 3, 2026 purchase of 6,551 shares was not affirmed as being made under a pre-arranged trading plan.

What is the nature of the transaction reported for Camp4 Therapeutics (CAMP) CFO on August 3, 2026?

The transaction is a purchase of common stock in a private placement’s second closing, not an open-market trade. CFO Kelly Gold acquired 6,551 shares at $1.65 per share pursuant to a Securities Purchase Agreement with the issuer and investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 05:08 PM Accepted by SEC EDGAR 08/05/2026 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gold Kelly

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		P		6,551	A	$1.65(1)	74,428	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Remarks:

	/s/ Kelly Gold	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)